Thyroid disease following the administration of Thorotrast

“…Shortterm changes in thyroid function were not studied. In addition to clinical studies, multiple case reports of patients with euthyroid autonomous nodules, nontoxic goiter, or asymptomatic Graves' disease have documented the development of thyrotoxicosis after CT scanning with contrast (amidotrizoate) 7, coronary angiography (unknown agent) (8), IVP (unknown agent) (6), carotid angiography (iophendylate) (9), and cervical myelography (iophendylate) (14). Our protocol studied a large group (56 patients) with normal findings on thyroid examinations and evaluated the short-term effect of two commonly used iodinated contrast agents, Renografin and Omnipaque.…”

Section: Discussionmentioning

confidence: 99%

Short-Term Effects of Coronary Angiographic Contrast Agents on Thyroid Function

et al. 1997

View full text Add to dashboard Cite

Objective: To determine the effect of two iodine-containing contrast agents used for coronary angiography on subsequent thyroid hormone concentrations. Methods: We prospectively studied thyroid function in 56 patients, with no previous history of thyroid disease and normal findings on thyroid examinations, who underwent nonemergent cardiac catheterization. Thyroid hormone concentrations were assessed at baseline and at day 1 and day 7 after administration of a radiographic iodinated contrast agent (Renografin or Omnipaque). Results: Use of Omnipaque and Renografin was not associated with significant changes in thyroid-stimulating hormone, total thyroxine, triiodothyronine resin uptake, free thyroxine index, or total triiodothyronine. Three patients had slightly increased thyroid-stimulating hormone concentrations at 7 days after angiography. Conclusion: Administration of iodinated contrast agents for cardiac catheterization does not result in hyperthyroidism in patients with previously normal findings on thyroid examination.

show abstract

“…Thorotrast was first used in Britain in Edinburgh mainly for cerebral angiography in neurosurgical patients, and a series of Edinburgh patients has been studied in detail. Certain long-term complications have appeared, including progressive loss of splenic function (Langlands & Williamson, 1967), an increased incidence of thyroid disease (Langlands & Hermann, 1967), chromosomal damage (Buckton et al, 1967;Buckton & Langlands, 1973) and an excess of deaths from malignant disease, in particular cancer of the liver (Ascroft & MacCabe, 1962;Boyd et al, 1968). The purpose of the present paper is to update the mortality figures for those patients in this series who had received intra-arterial Thorotrast for cerebral angiography, and to draw attention to the recent appearance of cases of ASL arising from the past use of Thorotrast in Edinburgh and elsewhere.…”

mentioning

confidence: 99%

Angiosarcoma of the liver: a marker tumour for the late effects of Thorotrast in Great Britain

Baxter¹,

Langlands²,

Anthony³

et al. 1980

Br J Cancer

View full text Add to dashboard Cite

Summary.-Monitoring the incidence of angiosarcoma of the liver (ASL) between 1974 and 1977 has led to the confirmation by a panel of pathologists of 7 new cases of ASL in patients who had received intra-arterial Thorotrast for radiological investigations. A cluster of cases has appeared in and around Edinburgh where the use of Thorotrast was pioneered in Britain in 1933-48, and a mortality study of 113 Edinburgh patients has confirmed a significant excess of liver-tumour deaths in recent years. Deaths from cancers of the lung and breast, and from hepatic cirrhosis, were also in excess, but the limitations of the death-certificate data are described in relation to the clinical and pathological findings. Thorotrast was also used in other centres, and an increased incidence in Britain of liver tumours attributable to this agent is indicated.

show abstract

Thyroid disease following the administration of Thorotrast

Cited by 8 publications

References 4 publications

Haemangioendothelioma (Kupffer cell angiosarcoma), myelofibrosis, splenic atrophy, and myeloma paraproteinaemia after parenteral thorotrast administration.

Haemangioendothelioma (Kupffer cell angiosarcoma), myelofibrosis, splenic atrophy, and myeloma paraproteinaemia after parenteral thorotrast administration.

Short-Term Effects of Coronary Angiographic Contrast Agents on Thyroid Function

Angiosarcoma of the liver: a marker tumour for the late effects of Thorotrast in Great Britain

Contact Info

Product

Resources

About